ArticleFrontiers in pediatrics2025
Global, regional, and national burden of pediatric nasopharyngeal carcinoma (1990-2021) and projections of future disease burden trends.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Pediatric nasopharyngeal carcinoma (NPC) is an exceedingly rare and often overlooked disease. However, early detection of this condition is a decisive factor in its prognosis. This study aims to quantify the disease burden and epidemiological trends of pediatric nasopharyngeal carcinoma over a 30-year period (1991-2021) and provide projections for future disease burden. Methods: Comprehensive data on pediatric NPC from 1990 to 2021 were obtained from the Global Burden of Disease study. This dataset includes information on the incidence of pediatric NPC, disaggregated by gender. The Joinpoint regression model was used to identify turning points in epidemiological trends, while decomposition analysis helped identify the factors driving these trends. To forecast future incidence rates, the Norpred model were applied. Results: In 1990, the estimated global number of pediatric NPC cases was 1,269 (1,119-1,422), with 764 (663-892) cases in boys and 505 (427-592) cases in girls. The global ASIR of pediatric NPC in 1990 was 0.07 (0.06-0.08), with rates of 0.09 (0.07-0.10) in boys and 0.06 (0.05-0.07) in girls. By 2021, the estimated global number of pediatric NPC cases decreased to 966 (796-1,152), including 576 (444-725) cases in boys and 390 (326-501) cases in girls. The global ASIR of pediatric NPC in 2021 was 0.05 (0.04-0.06), with rates of 0.06 (0.04-0.07) in boys and 0.04 (0.03-0.05) in girls. Joinpoint regression analysis indicated stable epidemiological trends from 1990 to 2021, with a slight decline in both sexes. Based on the Nordpred model, the projected 2046 ASIR for pediatric NPC is 0.09 (male: 0.10; female: 0.80), with 1,169 total cases (boys: 680; girls: 489). Conclusion: The incidence of pediatric NPC is relatively low overall, with a slight downward trend in its epidemiological trajectory.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.